X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Curreio’s state-of-the-art cryo-EM platform in combination with Iktos’ Spaya™ retrosynthesis AI technology, will be used to facilitate the rapid and cost-effective design of novel preclinical drug candidates for an undisclosed target.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Curreio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 08, 2023
Details:
Under the collaboration agreement, Iktos will apply its new ‘DockAI’ technology to expedite the discovery of novel antimalarial drug candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medicines for Malaria Venture
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 23, 2022
Details:
ONO will acquire exclusive worldwide rights to develop and commercialize small molecule compounds discovered in the collaboration. Iktos will receive research funding plus milestone payments based on achievement of certain milestones.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
